Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.
N. C. Nadia de Cassia Noronha,Amanda Mizukami,Carolina Caliari-Oliveira,Juçara Gastaldi Cominal,Jose Lucas M. Rocha,Dimas Tadeu Covas,Kamilla Swiech,Kelen C. R. Malmegrim +7 more
Reads0
Chats0
TLDR
Current priming approaches that aim to increase MSC therapeutic efficacy, including priming with cytokines and growth factors, hypoxia, pharmacological drugs, biomaterials, and different culture conditions, as well as other diverse molecules, are revised from current and future perspectives.Abstract:
Multipotent mesenchymal stromal cells (MSC) have been widely explored for cell-based therapy of immune-mediated, inflammatory, and degenerative diseases, due to their immunosuppressive, immunomodulatory, and regenerative potentials. Preclinical studies and clinical trials have demonstrated promising therapeutic results although these have been somewhat limited. Aspects such as low in vivo MSC survival in inhospitable disease microenvironments, requirements for ex vivo cell overexpansion prior to infusions, intrinsic differences between MSC and different sources and donors, variability of culturing protocols, and potency assays to evaluate MSC products have been described as limitations in the field. In recent years, priming approaches to empower MSC have been investigated, thereby generating cellular products with improved potential for different clinical applications. Herein, we review the current priming approaches that aim to increase MSC therapeutic efficacy. Priming with cytokines and growth factors, hypoxia, pharmacological drugs, biomaterials, and different culture conditions, as well as other diverse molecules, are revised from current and future perspectives.read more
Citations
More filters
Journal ArticleDOI
Shattering barriers toward clinically meaningful MSC therapies.
Oren Levy,Rui Kuai,Rui Kuai,Erika M. J. Siren,Deepak Bhere,Yuka Milton,Nabeel Nissar,Michael De Biasio,Martina Heinelt,Brock Reeve,Reza Abdi,Meshael Alturki,Mohanad Fallatah,Abdulaziz Almalik,Ali H. Alhasan,Khalid Shah,Khalid Shah,Jeffrey M. Karp +17 more
TL;DR: The major clinical challenges with MSC therapies, the details of these challenges, and the potential bioengineering approaches that leverage the unique biology of MSCs to overcome the challenges and achieve more potent and versatile therapies are discussed.
Journal ArticleDOI
Modulation of the Inflammatory Response and Bone Healing.
Masahiro Maruyama,Claire Rhee,Takeshi Utsunomiya,Ning Zhang,Masaya Ueno,Zhenyu Yao,Stuart B. Goodman +6 more
TL;DR: The principles of inflammation and bone healing are summarized, an update on cellular interactions and immunomodulation for optimal bone healing is provided and the resolution of inflammation with anti-inflammatory cytokines such as IL4, IL10, and IL13 is described.
Journal ArticleDOI
Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent.
TL;DR: Emerging evidences support the compelling possibility of using MSC-derived exosomes as a new form of therapy for treating several different kinds of disease such as heart, kidney, immune diseases, neural injuries, and neurodegenerative disease.
Journal ArticleDOI
Challenges and advances in clinical applications of mesenchymal stromal cells.
TL;DR: In this paper, the major challenges of mesenchymal stromal cells (MSCs) therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MMSs for COVID-19 pandemic disease.
Journal ArticleDOI
A Comparative Analysis of Multipotent Mesenchymal Stromal Cells derived from Different Sources, with a Focus on Neuroregenerative Potential.
Yuriy A. Petrenko,Irena Vackova,Kristyna Kekulova,Kristyna Kekulova,Milada Chudíčková,Zuzana Kočí,Karolina Turnovcova,Helena Kupcova Skalnikova,Petr Vodicka,Šárka Kubinová +9 more
TL;DR: The MSC secretome derived from all cell sources had a pronounced neurotrophic potential to stimulate the neurite outgrowth of DRG-neurons and reduce the cell death of neural stem/progenitor cells after H 2 O 2 treatment.
References
More filters
Journal ArticleDOI
Matrix elasticity directs stem cell lineage specification.
TL;DR: Naive mesenchymal stem cells are shown here to specify lineage and commit to phenotypes with extreme sensitivity to tissue-level elasticity, consistent with the elasticity-insensitive commitment of differentiated cell types.
Journal ArticleDOI
Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015
Gregory A. Roth,Catherine O. Johnson,Amanuel Alemu Abajobir,Foad Abd-Allah,Semaw Ferede Abera,Gebre Yitayih Abyu,Muktar Beshir Ahmed,Baran Aksut,Tahiya Alam,Khurshid Alam,François Alla,Nelson Alvis-Guzman,Stephen M. Amrock,Hossein Ansari,Johan Ärnlöv,Hamid Asayesh,Tesfay Mehari Atey,Leticia Avila-Burgos,Ashish Awasthi,Amitava Banerjee,Aleksandra Barac,Till Bärnighausen,Lars Barregard,Neeraj Bedi,Ezra Belay Ketema,Derrick A Bennett,Gebremedhin Berhe,Zulfiqar A Bhutta,Shimelash Bitew,Jonathan R. Carapetis,Juan Jesus Carrero,Deborah Carvalho Malta,Carlos A Castañeda-Orjuela,Jacqueline Castillo-Rivas,Ferrán Catalá-López,Jee Young Choi,Hanne Christensen,Massimo Cirillo,Leslie T. Cooper,Michael H. Criqui,David K. Cundiff,Albertino Damasceno,Lalit Dandona,Lalit Dandona,Rakhi Dandona,Rakhi Dandona,Kairat Davletov,Samath D Dharmaratne,Prabhakaran Dorairaj,Manisha Dubey,Rebecca Ehrenkranz,Maysaa El Sayed Zaki,Emerito Jose Aquino Faraon,Alireza Esteghamati,Talha Farid,Maryam S. Farvid,Valery L. Feigin,Eric L. Ding,Gerry Fowkes,Tsegaye Tewelde Gebrehiwot,Richard F. Gillum,Audra Gold,Philimon Gona,Rajeev Gupta,Tesfa Dejenie Habtewold,Nima Hafezi-Nejad,Tesfaye Hailu,Gessessew Bugssa Hailu,Graeme J. Hankey,Hamid Yimam Hassen,Kalkidan Hassen Abate,Rasmus Havmoeller,Simon I. Hay,Simon I. Hay,Masako Horino,Peter J. Hotez,Kathryn H. Jacobsen,Spencer L. James,Mehdi Javanbakht,Panniyammakal Jeemon,Denny John,Jost B. Jonas,Yogeshwar Kalkonde,Chante Karimkhani,Amir Kasaeian,Yousef Khader,Abdur Rahman Khan,Young-Ho Khang,Sahil Khera,Abdullah T Khoja,Jagdish Khubchandani,Daniel Kim,Dhaval Kolte,Soewarta Kosen,Kristopher J Krohn,G Anil Kumar,Gene F. Kwan,Dharmesh Kumar Lal,Anders Larsson,Shai Linn,Alan D. Lopez,Paulo A. Lotufo,Hassan Magdy Abd El Razek,Reza Malekzadeh,Mohsen Mazidi,Toni Meier,Kidanu Gebremariam Meles,George A. Mensah,Atte Meretoja,Haftay Berhane Mezgebe,Ted R. Miller,Erkin M. Mirrakhimov,Shafiu Mohammed,Andrew E. Moran,Kamarul Imran Musa,Jagat Narula,Bruce Neal,Frida Namnyak Ngalesoni,Grant Nguyen,Carla Makhlouf Obermeyer,Mayowa O. Owolabi,George C Patton,João Mário Pedro,Dima M. Qato,Mostafa Qorbani,Kazem Rahimi,Rajesh Kumar Rai,Salman Rawaf,Antonio Luiz Pinho Ribeiro,Saeid Safiri,Joshua A. Salomon,Itamar S. Santos,Milena M Santric Milicevic,Benn Sartorius,Aletta E. Schutte,Sadaf G. Sepanlou,Masood Ali Shaikh,Min-Jeong Shin,Mehdi H. Shishehbor,Hirbo Shore,Diego Augusto Santos Silva,Eugene Sobngwi,Saverio Stranges,Soumya Swaminathan,Rafael Tabarés-Seisdedos,Niguse Tadele Atnafu,Fisaha Haile Tesfay,Jarnail Singh Thakur,Amanda G. Thrift,Roman Topor-Madry,Thomas Truelsen,Stefanos Tyrovolas,Kingsley N. Ukwaja,Olalekan A. Uthman,Tommi Vasankari,Vasiliy Victorovich Vlassov,Stein Emil Vollset,Tolassa Wakayo,David A Watkins,Robert G. Weintraub,Andrea Werdecker,Ronny Westerman,Charles Shey Wiysonge,Charles D.A. Wolfe,Abdulhalik Workicho,Gelin Xu,Yuichiro Yano,Paul S. F. Yip,Naohiro Yonemoto,Mustafa Z. Younis,Chuanhua Yu,Theo Vos,Mohsen Naghavi,Christopher J L Murray +173 more
TL;DR: The GBD (Global Burden of Disease) 2015 study integrated data on disease incidence, prevalence, and mortality to produce consistent, up-to-date estimates for cardiovascular burden, finding that CVDs remain a major cause of health loss for all regions of the world.
Journal ArticleDOI
Mesenchymal stem cells: immune evasive, not immune privileged
TL;DR: Protecting MSCs from immune detection and prolonging their persistence in vivo may improve clinical outcomes and prevent patient sensitization toward donor antigens.
Journal ArticleDOI
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction
Luciano C. Amado,Anastasios Saliaris,Karl H. Schuleri,Marcus E. St. John,Jin Sheng Xie,Stephen M. Cattaneo,Daniel J. Durand,Torin P. Fitton,Jin Qiang Kuang,Garrick C. Stewart,Stephanie Lehrke,William W. Baumgartner,Bradley J. Martin,Alan W. Heldman,Joshua M. Hare +14 more
TL;DR: The results of a randomized study of bone-marrow-derived mesenchymal stem cells, administered to pigs, which offer several new insights regarding cellular cardiomyoplasty demonstrate that the direct injection of cellular grafts into damaged myocardium is safe and effective in the perii-nfarct period.
Journal ArticleDOI
A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype
TL;DR: This study suggests that hMSCs can be polarized by downstream TLR signaling into two homogenously acting phenotypes, and suggests that MSC polarization provides a convenient way to render these heterogeneous preparations of cells more uniform while introducing a new facet to study.
Related Papers (5)
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Jacques Galipeau,Luc Sensebé +1 more